RNF38, or Ring Finger Protein 38, belongs to the RING-finger family of proteins, characterized by a specific zinc-binding domain known as the RING domain. Proteins with RING domains are commonly associated with ubiquitination processes. Ubiquitination is a post-translational modification in which ubiquitin, a small protein, is covalently attached to target proteins, marking them for various fates such as degradation, localization, or modulation of activity. RNF38, as a RING-finger E3 ubiquitin ligase, facilitates the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific substrate proteins. Through its E3 ligase activity, RNF38 plays a role in determining the specificity of ubiquitination by recognizing and binding to particular substrate proteins, thereby influencing various cellular pathways and processes.
Inhibitors targeting RNF38 would be molecules devised to modulate the function, ubiquitin ligase activity, or stability of the RNF38 protein. Given RNF38's role in ubiquitination, inhibiting its activity could have wide-ranging effects on cellular protein homeostasis and other ubiquitin-dependent processes. Potential RNF38 inhibitors might comprise small molecules that bind directly to the protein, particularly its RING domain, altering its E3 ligase activity. Such inhibition could hinder the ubiquitination of RNF38's substrate proteins, potentially leading to their accumulation or altered function within the cell. Another strategy could focus on molecules that modulate post-translational modifications of RNF38, which might influence its activity, substrate recognition, or interactions with other ubiquitination machinery components. Additionally, molecular tools, such as RNA interference or antisense oligonucleotides, could be employed to modulate RNF38 expression at the genetic level. Exploring the effects of RNF38 inhibition can provide insights into its specific roles in the ubiquitination pathway and how it shapes the cellular protein landscape. Such investigations would deepen our understanding of protein turnover, cellular signaling, and the intricate regulation of protein functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor, potentially influencing the ubiquitin-proteasome system and RNF38. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific proteasome inhibitor, potentially impacting the ubiquitin-proteasome pathway and RNF38. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, affecting protein neddylation, which can influence ubiquitin ligase activity and potentially RNF38. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 stabilizes p53 by inhibiting MDM2, another E3 ubiquitin ligase. This might indirectly affect other E3 ligases, including RNF38. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is a cell-permeable ubiquitin-activating enzyme (E1) inhibitor, potentially affecting the ubiquitin-proteasome system and RNF38. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Similar to thalidomide, lenalidomide affects protein degradation and might have an indirect impact on RNF38. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG inhibits Hsp90, affecting the stability of its client proteins. This might indirectly influence the stability or expression of RNF38. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A inhibits the vacuolar type H+-ATPase, affecting lysosomal acidification and potentially protein degradation pathways influencing RNF38. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a potent proteasome inhibitor, which by affecting the ubiquitin-proteasome system, might influence RNF38. | ||||||